Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-12 · 43 (12) · 1397-1404
DOI: 10.1002/phar.2874 ↗At a glance
Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-09-15. Written by Andrew Willeford and 1 co-authors. Institution: UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA. Major MEDLINE topics: Disopyramide, Cardiomyopathy, Hypertrophic. Cited 13 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Hypertrophic cardiomyopathy (HCM) is a genetic disorder for which first‐line treatments for obstructive HCM (oHCM) include beta‐blockers, non‐dihydropyridine calcium channel blockers, and disopyramide for refractory cases. Mavacamten, a selective cardiac myosin inhibitor, is indicated for symptomatic oHCM to improve functional capacity and symptoms. Use of disopyramide and mavacamten together is not recommended due to concerns of additive negative inotropic effects. Transitioning from disopyramide to mavacamten may be preferred to avoid adverse effects and frequent administration, however, the best approach for making the transition has not been established. Cases We present a series of seven patients with oHCM who transitioned from disopyramide to mavacamten and underwent echocardiograms mandated by a Risk Evaluation and Mitigations Strategies program. Two methods were employed. The first approach, involving washout of disopyramide before starting mavacamten, resulted in worsening of heart failure symptoms in the first two cases. The second approach, involving tapering disopyramide when starting mavacamten, was successfully implemented in the last five cases, with no adverse effects or worsening of systolic dysfunction.
Conclusion
Our method of tapering disopyramide when starting mavacamten using a stepwise approach is feasible and safe. Our report fulfills an unmet need by serving as a guide for other clinicians who seek to transition their patients from disopyramide to mavacamten.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA.
- Division of Cardiology, Department of Medicine, University of California San Diego, San Diego, California, USA.
ORCID profiles: Andrew Willeford, Jorge Silva Enciso
Cite
APA
Willeford, A., & Silva Enciso, J. (2023). Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(12), 1397-1404. https://doi.org/10.1002/phar.2874
Vancouver
Willeford A, Silva Enciso J. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(12):1397-1404. doi:10.1002/phar.2874
BibTeX
@article{Willeford2023,
author = {Willeford, Andrew and Silva Enciso, Jorge},
title = {Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {12},
pages = {1397--1404},
doi = {10.1002/phar.2874}
}
EUVIMED